Grail's cancer screening test wins tepid support from an FDA advisory panel
The committee raised concerns about its effectiveness after the test failed a UK study earlier this year.
Intelligence
The parties
Activity
The committee raised concerns about its effectiveness after the test failed a UK study earlier this year.
Intelligence
Activity